INVESTMENTS THAT MATTER

Agent Capital is a healthcare venture capital firm focused on investing in novel, differentiated therapeutics and treatments that address unmet patient needs.

Across all stages of development, we align ourselves with scientists, entrepreneurs and other investors to develop the next generation of healthcare innovations that will have a positive impact on patients’ lives.

OUR PROVEN STRATEGY

At Agent Capital, we proactively guide biotech companies to milestones and exits.

With a balanced investment approach and a deep understanding of biopharma’s pipeline pressures, we are committed to making investments that move healthcare forward – no matter the stage or investment type.

TYPICALLY, OUR KEY INVESTMENT AREAS OF FOCUS INCLUDE:

Rare Diseases
Oncology
Neurology
Immunology
Learn More

Featured Portfolio Company

Skyhawk Therapeutics

Carisma Therapeutics

Entrada Therapeutics

Pliant Therapeutics

Pyxis Oncology

Dragonfly Therapeutics

Freenome

ImCheck Therapeutics

Dice Therapeutics

Orbus Therapeutics

View Full Portfolio

Featured News

News | November 14, 2022

Ionis, Metagenomi pen Big Pharma-sized genetic target pact that could total almost $3B

Read More

Press Release | November 7, 2022

Zenas BioPharma Secures $118 Million to Advance Its Broad Pipeline of Autoimmune Disease Therapeutics

Read More

Press Release | October 11, 2022

DICE Therapeutics Announces Positive Topline Data from Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for Psoriasis

Read More

View All